Search Results - crystal+mackall

4 Results Sort By:
Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)
Abstract: Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to...
Published: 4/8/2024   |   Inventor(s): Terry Fry, Crystal Mackall, Rimas Orentas, Haiying Qin, Waleed Haso
Keywords(s): Acute Lymphoblastic Leukemia, ALL, BISPECIFIC, Bivalent, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
Abstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.  Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  Thus,...
Published: 4/8/2024   |   Inventor(s): Rimas Orentas, Nirali Shah, Ira Pastan, Crystal Mackall, Dimiter Dimitrov
Keywords(s): Acute Lymphoblastic Leukemia, adoptive cell therapy, ALL, B-CELL, CD22, Chimeric antigen receptors (CARs), Chronic lymphocytic leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Immunotherapy, pediatric
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)
Abstract: Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually...
Published: 8/14/2024   |   Inventor(s): Haiying Qin, Terry Fry, Crystal Mackall
Keywords(s): Acute Lymphoblastic Leukemia, ALL, BICISTRONIC, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration
Chimeric Antigen Receptors to CD276 for Treating Cancer
Abstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.  Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  By...
Published: 4/8/2024   |   Inventor(s): Crystal Mackall, Yongzhi Cui
Keywords(s): adoptive cell therapy, ANTIBODY, antigen-binding fragment, CAR, Neuroblastoma
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology